Product category:
Laboratory and scientific consultancy services
News Release from: Michelson Diagnostics
Edited by the Laboratorytalk Editorial
Team on 02 October 2007
Improving cancer survival through
imaging
Michelson Diagnostics awarded £325k grant from the UK Technology Strategy Board to support development of a groundbreaking OCT imaging technology to revolutionise cancer diagnosis and treatment
The collaboration is between MDL, University of Cardiff, Gloucestershire Hospitals NHS Foundation Trust, National Physical Laboratory, semiconductor specialist Kamelian and medical imaging systems specialist Tactiq The funded project, 'Omicron', will last two years, and will focus on development of an in-vivo imaging probe, using optical coherence tomography (OCT), to obtain high resolution sub-surface images of cancerous tissue, operating at the new, untried wavelength of 1um
This article was originally published on Laboratorytalk on 13 Apr 2007 at 8.00am (UK)
Related stories
Probing tissue morphology in biological specimens
Michelson Diagnostics has announced the EX1301 OCT microscope, which provides high-resolution sub-surface images from much deeper into the sample than is possible with conventional microscopes
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
Leading OCT researcher Professor Wolfgang Drexler, director of research at the University of Cardiff dept of optometry and vision science, said: "We believe that images acquired at 1um wavelength will offer improved contrast and resolution that will help clinicians to distinguish between healthy and cancerous tissue".
Clinicians frequently take biopsy samples of tissue for laboratory analysis by pathologists when diagnosing, assessing, treating and monitoring cancer.
This can be inefficient, expensive and time-consuming.
The biopsy may be poorly targeted on the tumour, and results from the analysis can take weeks to come back.
Nick Stone, head of biophotonics at Gloucestershire Hospitals NHS Foundation Trust, added: "OCT scanning has the exciting potential of both guiding and reducing the dependence on biopsies, which could speed up cancer diagnosis and treatment, reducing the pressure on overloaded pathology departments, and improve outcomes from cancer surgery".
Jon Holmes, CEO of MDL said "We are very excited about winning this grant as it has enabled a collaboration of world class academic and industrial partners, to develop products which will make an enormous difference to the lives of many of those with cancer".
• Michelson Diagnostics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
